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258Durability of treatment effect with polidocanol
endovenous microfoam on varicose vein symptoms
and appearance (VANISH-2)
Kenneth L. Todd III, MD,a and David I. Wright, MD,b,c for the VANISH-2 Investigator Group, Dothan,
Ala; Philadelphia, Pa; and London, United KingdomObjective: The objectives of this study were to assess the
durability of response to treatment with polidocanol endove-
nous microfoam (Varithena; Provensis Ltd, a BTG Interna-
tional group company) and to assess the long-term safety of
the study patients.
Methods: This report presents efﬁcacy and safety data from the
day after visit 5/week 8 (the primary end point of the study)
through the 1-year study visit. As the approved dose concen-
tration is 1%, this analysis focuses on those patients who were
randomized to polidocanol endovenousmicrofoam 1% at study
visit 2. Because the objective of the 1-year analysis was to assess
the durability of response to treatment with polidocanol
endovenousmicrofoam1%, the1-year efﬁcacy analysesbasedon
the efﬁcacy population included all patients who were ran-
domized and received at least one treatment with polidocanol
endovenous microfoam 1%. Efﬁcacy end points in the Polido-
canolEndovenousMicrofoamVersusVehicle for theTreatment
of Saphenofemoral Junction Incompetence (VANISH-2) trial
were evaluated at 1 year (n[ 221; 96% of those completed the
primary end-point measurement at week 8) and included the
following: Varicose Vein Symptoms Questionnaire (VVSymQ,
Provensis Ltd) score, an assessment of symptoms by patients
using electronic daily diaries; Independent Photography
Review: Visible Varicose Veins (IPR-V3) and Patient Self-
assessment of Visible Varicose Veins (PA-V3) scores, the
assessment of appearance by an Independent Physician Review
panel and by patient self-assessment, respectively; duplex ul-
trasound response (physiologic response to treatment); Venous
Clinical Severity Score (disease severity); and Venousthe Southeast Vein and Laser Center, Dothana; and BTG
ternational, Philadelphiab and London.c
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Results: Of the 230 patients who completed visit 5/week 8,
56 received polidocanol endovenous microfoam 1% at visit
2/week 0 and were subsequently assessed for efﬁcacy at visit 5/
week 8 and visit 10/1 year (one patient of the 57 who completed
visit 5/week 8 received a nonpolidocanol endovenousmicrofoam
intervention and was not included in the assessment). At 1 year
after the ﬁrst study treatment, patients treated with polidocanol
endovenous microfoam demonstrated consistent, durable, and
clinically meaningful improvements in symptoms, as measured by
reductions in mean VVSymQ score; appearance, as measured by
IPR-V3(clinicianassessment)andPA-V3(patient self-assessment)
scores; disease severity, as measured by the Venous Clinical
Severity Score; and quality of life, as measured by the VEINES-
QOLscore.At1year, therewerenonewvenous thrombusadverse
events (VTAEs) and no clinically important sequelae in patients
who had a VTAE in the study. In addition, there were no serious
adverse events that were determined by the investigator to be
related to the studydrug.Nonew safety signalswere identiﬁed. In
patients who previously had a VTAE, none had a recurrence of
thrombus or evidence of post-thrombotic syndrome at 1 year.
Conclusions: Treatment with polidocanol endovenous micro-
foam 1% led to durable, clinically meaningful, and ongoing
improvements at 1 year in varicose vein symptoms and
appearance. Serious adverse events were those expected during
long-term follow-up of the population of patients studied and
were unrelated to treatment. (J Vasc Surg: Venous and Lym
Dis 2015;3:258-64.)
During the past decade, there has been renewed
interest in the treatment of chronic venous insufﬁciency
and resultant varicose veins, mainly because of new ad-
vances in endovenous treatment, including ultrasound-
guided foam sclerotherapy.1 In 1993, Cabrera invented
a technique that produced foams of polidocanol, which
were made with O2 or O2/CO2 gas mixes, and conse-
quently the ﬁrst stable, physiologically absorbable micro-
foam.2 This foam has been used to treat superﬁcial
venous disease, venous malformations, and leg ulcers.3
Foams contact the venous endothelium more efﬁciently
and therefore are signiﬁcantly more efﬁcacious than
liquid sclerosant for the treatment of larger veins,
including the saphenous trunk veins.4,5 Physician-
compounded foam is frequently used and has been rela-
tively safe.6 However, there are case reports of signiﬁcant
neurologic events, including stroke, seizure, and tran-
sient ischemic attack, after treatment with foams made
with room air.7-11
Fig 1. Polidocanol Endovenous Microfoam Versus Vehicle for
the Treatment of Saphenofemoral Junction Incompetence
(VANISH-2) study design.
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for the Treatment of Saphenofemoral Junction Incompe-
tence (VANISH-2) trial studied proprietary low-nitrogen
pharmaceutical-grade polidocanol endovenous microfoam
(Varithena; Provensis Ltd, a BTG International group com-
pany) and is one of two pivotal phase 3 studies comparing
the efﬁcacy of Varithena with placebo that led to market
approval from the U.S. Food and Drug Administration
(FDA). Varithena 1% is indicated for the treatment of incom-
petent great saphenous veins (GSVs), accessory saphenous
veins, and visible varicosities of the GSV system above and
below the knee and improves the symptoms of superﬁcial
venous insufﬁciency and the appearance of visible varicosities.
Polidocanol endovenous microfoam 1% is unique in its gas
composition and in that it is prepared under strict good
manufacturing practices and, importantly, that its gas
mixture (O2:CO2 [65:35]) contains only trace amounts of
nitrogen (<0.8%), thereby greatly minimizing the risk of
gas embolic adverse events. The primary and secondary efﬁ-
cacy end points, improvement in varicose vein symptoms and
appearance, were assessed by three new validated clinical
outcome assessment instruments developed in alignment
with FDA guidance for patient-reported outcome mea-
sures12: (1) a patient self-assessment of the ﬁve most impor-
tant symptoms of varicose veins (Varicose Vein Symptoms
Questionnaire [VVSymQ], Provensis Ltd); (2) a patient
self-assessment of appearance of visible varicose veins (Patient
Self-assessment of Visible Varicose Veins [PA-V3]); and (3)
an independent photographic review of visible varicose veins
by experts in venous disease (Independent Photography
Review: Visible Varicose Veins [IPR-V3]).
In the VANISH-2 study, of the 232 patients enrolled,
those treated with polidocanol endovenous microfoam at
concentrations of 0.5% and 1.0% had signiﬁcantly superior
results to those treated with placebo, with a larger improve-
ment in symptoms (change in VVSymQ score: 6.01
and 5.06, respectively, vs 2.00; P < .0001) and greater
improvements in physician and patient assessments of
appearance than with placebo (P < .0001). These ﬁndings
were supported by the results of duplex ultrasound
response. Of the 230 patients treated with either blinded
or open-label polidocanol endovenous microfoam, 60%
had an adverse event compared with 39% of placebo
patients; 95% of all adverse events were mild or moderate.
No pulmonary emboli were reported, and no clinically
important neurologic or visual events were reported. The
most common adverse events in patients treated with poli-
docanol endovenous microfoam were retained coagulum,
leg pain, and superﬁcial thrombophlebitis; most were
related to treatment and resolved without sequelae.13
Here, we report the efﬁcacy and safety data for patients
who were treated with polidocanol endovenous microfoam
1% at baseline (visit 2/week 0), from visit 5/week 8
through the year 1 visit.
METHODS
Study design. VANISH-2 was a randomized, double-
blind, multicenter, parallel group study designed toevaluate the efﬁcacy and safety of two dose concentrations
of polidocanol endovenous microfoam (0.5% and 1.0%)
compared with placebo (Fig 1) at 8 weeks and at 1 year. A
subtherapeutic polidocanol endovenous microfoam dose
concentration of 0.125% was indistinguishable from the
active test dose (1.0%) and therefore provided a procedural
blind for the physician performing the procedure. The
study population consisted of male and female patients
aged 18 to 75 years who had saphenofemoral junction
(SFJ) incompetence (SFJ reﬂux >0.5 second) due to reﬂux
of the GSV or major accessory veins as determined by
duplex ultrasound and superﬁcial venous disease man-
ifested by symptoms and visible varicosities. No patients in
this study received treatment with polidocanol endovenous
microfoam for branch varicose veins only. Entry criteria
required patients to have major axial reﬂux, and all patients
in this study received treatment to the GSV.
Study treatments. At the start of VANISH-2, patients
were randomized 1:1:1:1 to receive endovenous injections
of polidocanol endovenous microfoam 0.125%, 0.5%, or
1% or placebo in one or two treatment sessions. Eligible
patients received up to 15 mL of foam at each treatment
session, 1 week apart. At or within 2 weeks after visit
5/week 8, at visit 6 or 7, all patients were offered one or
two optional additional open-label treatment sessions with
up to 15 mL of polidocanol endovenous microfoam 1.0%
each, 1 week apart.
The primary objective at 1 year was to assess the dura-
bility of treatment effect with polidocanol endovenous
microfoam 1% during 1 year. Therefore, during this assess-
ment period, no new patients were screened, enrolled, or
treated. Because the approved dose concentration is poli-
docanol endovenous microfoam 1%, this analysis focuses
on those patients who were randomized to polidocanol
endovenous microfoam 1% at visit 2/week 0.
Study patients. Of the 232 patients at baseline, 221
patients (95.3%) completed the year 1 study visit; and of
the 58 of those who received polidocanol endovenous
microfoam 1% at visit 2/week 0, 98.3% completed the
year 1 study visit (visit 10) (Table I). Across analysis
Table I. Patient disposition from blinded treatment through visit 10/year 1
All treated patients
(N ¼ 232), No. (%)
Randomized patients who received
polidocanol injectable foam 1% at
visit 2 (n ¼ 58), No. (%)
Treated at baseline (visit 2) 232 (100) 58 (100)
Completed week 8 (visit 5) 230 (99.1) 57 (98.3)
Received open-label polidocanol injectable foam 1% (visit 6) 155 (66.8) 25 (43.1)
Received additional open-label polidocanol injectable foam 1% (visit 7) 49 (21.1) 6 (10.3)
Completed 1 year (visit 10) 221 (95.3) 57 (98.3)
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1 study visit (visit 10) ranged from 93.0% for patients in the
placebo group to 98.3% in the polidocanol endovenous
microfoam 1% group. Table II lists the baseline charac-
teristics of all treated patients and those treated with poli-
docanol endovenous microfoam 1% at visit 2/week 0.
Ethics. This study was conducted under and in
compliance with the principles of the International Confer-
ence on Harmonisation Good Clinical Practice and the
Declaration of Helsinki (1996). The protocol and all asso-
ciated materials were approved by a central Institutional
Review Board (Schulman Associates IRB, Inc, Cincinnati,
Ohio) or local Institutional Review Boards. All patients
provided written informed consent.
Efﬁcacy assessments. To assess durability of response,
the primary symptom efﬁcacy assessment was the change
in VVSymQ score from baseline (visit 2/week 0) through
week 8 (visit 5) to 1 year after treatment. Cosecondary
appearance efﬁcacy assessments at 1 year after treatment
were the IPR-V3 score and the PA-V3 score.
The primary analysis of efﬁcacy in VANISH-2 was
patient assessment of symptoms by VVSymQ. Patients
used an electronic diary each evening of the 7 days imme-
diately before a study visit to assess the intensity and dura-
tion of nine varicose vein symptoms, ﬁve of which had
been rated by patients to be the most important (heaviness,
achiness, swelling, throbbing, itchinessdthe HASTI symp-
toms) and composed the VVSymQ score. These symptoms
were assessed with a 6-point duration scale that ranged
from 0 (none of the time) to 5 (all of the time).Table II. Baseline characteristics (at visit 2) of all treated patien
1% at visit 2
All treat
(N ¼
Age, mean years (minimum, maximum) 50.8 (2
Sex, female 72
Race, white 92
BMI, kg/m2, mean 29
GSV diameter, mean mm (minimum, maximum) 8.7 (3
CEAP clinical class
C2 (varicose veins) 31
C3 (edema) 40
C4 (skin changes) 22
C5/C6 (healed; active ulcers) 5
BMI, Body mass index; CEAP, clinical, etiologic, anatomic, and pathophysiologTo anchor the measured symptom reductions to clini-
cally meaningful improvement, a separate questionnaire
was completed at 1 year that evaluated the patient’s global
assessment of overall beneﬁt from treatment (Patient
Global Impression of Change [PGIC]). Patients who
reported overall improvements in the PGIC, measured as
“much improved” or “moderately improved,” were
compared at visit 5/week 8 and at year 1 after treatment.
Duplex ultrasound response was assessed as a marker of
physiologic response to and durability of treatment. As in
the original 8-week study,13 duplex ultrasound response
was deﬁned in the study as follows:
B Elimination of reﬂux through the SFJ, as measured in the
GSV 1 to 3 cm distal to the SFJ, where reﬂux is deﬁned
as retrograde ﬂow of >0.5 second following augmenta-
tion of ﬂow by calf compression and subsequent release
(shown on duplex ultrasound and spectral display); or
B Complete occlusion of the target incompetent veins
(GSV or major accessory veins) as measured within
10 cm of the SFJ, where occlusion is deﬁned as the
demonstration of incompressibility of the target vein
with the absence of any ﬂow by duplex ultrasound.
Safety evaluations. In the long-term follow-up period,
safety was assessed by collecting serious adverse events
(SAEs) at each study visit and through monitoring and
follow-up of venous thrombus adverse events (VTAEs).
VTAEs were deﬁned as incidence of new venous thrombus
or pulmonary embolus. All patients who had a VTAEts and patients who received polidocanol injectable foam
ed patients
232)
Patients who received polidocanol injectable
foam 1% at visit 2 (n ¼ 58)
1, 73) 50.0 (21, 70)
.8% 75.9%
.7% 91.4%
.5 28.4
.1, 19.4) 9.0 (3.8, 19.4)
.9% 34.5%
.1% 37.9%
.8% 24.1%
.2% 3.4%
ic classiﬁcation; GSV, great saphenous vein.
Fig 2. Distribution of Varicose Vein Symptoms Questionnaire (VVSymQ) scores at baseline, week 8, and year 1,
patients treated with polidocanol injectable foam 1% at VANISH-2 baseline (n ¼ 53).
Fig 3. Changes from baseline to week 8 and year 1 in Varicose
Vein Symptoms Questionnaire (VVSymQ) individual symptom
scores, patients treated with polidocanol injectable foam 1% at
VANISH-2 baseline (n ¼ 56).
JOURNAL OF VASCULAR SURGERY: VENOUS AND LYMPHATIC DISORDERS
Volume 3, Number 3 Todd and Wright 261during the main or open-label portion of the study were
reviewed with duplex ultrasound and speciﬁc assessment for
symptoms of post-thrombotic syndrome at the year 1 visit.
Statistical methods. To measure durability of response
in patients treated with polidocanol endovenous microfoam
1%, results from the visit 5/week 8 assessments for efﬁcacy
measurements (VVSymQ, IPR-V3, and PA-V3 scores) and
surrogate measures (ie, duplex ultrasound) were compared
with those obtained at the 1-year time point. The IPR-V3
score was the median rating of a panel consisting of three
qualiﬁed clinicians experienced in managing venous disease
who assessed the severity of each patient’s visible varicose
veins by reviewing standardized digital photographs. The
IPR-V3 used a 5-point scale ranging from 0 (no varicose
veins) to 4 (very severe varicose veins). Each reviewer
independently scored the photographs of the treatment leg
using a high-resolution monitor and specialized software
that allowed the reviewer to zoom in and out and to pan left
and right, approximating a live review.13 The PA-V3 score
was the patient’s self-assessment of the appearance of his or
her varicose veins. As in the IPR-V3, the PA-V3 used a
5-point scale, and each patient was instructed to choose one
of ﬁve statements that best described the actual (“live”)
appearance of the visible varicose veins of the study leg: not
at all noticeable (a score of 0), slightly noticeable (a score of
1), moderately noticeable (a score of 2), very noticeable (a
score of 3), or extremely noticeable (a score of 4). No
photographs were used, even at visit 5/week 8, for the pa-
tient to refer to as a reference point for how the leg looked
before treatment. The PA-V3 was conducted at baseline
(visit 2/week 0), visit 4/week 4, and visit 5/week 8.13
RESULTS
Efﬁcacy. Of the 230 patients who completed visit
5/week 8, 155 (66.8%) entered the 1-year extension and
received open-label polidocanol endovenous microfoam 1%
at visit 6 (within 2 weeks of visit 5), and 49 (21.1%) received
additional open-label treatment at visit 7 (visit 6 þ 1 week).
Of the 230 patients who completed visit 5/week 8 and who
had received polidocanol endovenous microfoam 1% at visit2/week 0, 56 were subsequently assessed for efﬁcacy at visit
5/week 8 and year 1. The overall distribution of VVSymQ
scores in this treatment cohort is listed in Fig 2. VVSymQ
scores at visit 5/week 8 continued to improve through visit
10/year 1. Results at visit 10/year 1 were as good as or
better than (64% with total VVSymQ scores of 3 or less at
week 8 vs 85% at year 1) those seen at visit 5/week 8. Re-
ductions from baseline in the individual symptom scores that
compose the VVSymQ score were also demonstrated, with
all ﬁve HASTI symptoms showing a continued decrease
from baseline (visit 2/week 0) to visit 5/week 8 to year 1
(Fig 3). In addition, improvements from baseline in
appearance as assessed by both the patients themselves (PA-
V3 score) and blinded experts reading standardized photo-
graphs (IPR-V3 score) were maintained, with a small trend
toward further improvement between visit 5/week 8 and
visit 10/year 1. Thus, the primary and secondary measures
of efﬁcacy (symptoms [VVSymQ score], patient assessment
of appearance [PA-V3 score], and physician assessment of
appearance [IPR-V3 score]) continued to improve at 1 year
(Fig 4). To provide photographic context, a comparative set
of IPR-V3 photographs and associated appearance scores
recorded at baseline and at year 1 after treatment are pro-
vided in Fig 5. The sponsor prospectively deﬁned a “clini-
cally meaningful response” to be those patients who
responded that they were moderately improved or much
Fig 4. Changes from baseline in primary and cosecondary efﬁcacy
end points, from week 8 through year 1 after treatment, patients
treated with polidocanol injectable foam 1%. CI, Conﬁdence in-
terval; IPR-V3, Independent Photography Review: Visible Vari-
cose Veins; PA-V3, Patient Self-assessment of Visible Varicose
Veins; VVSymQ, Varicose Vein Symptoms Questionnaire.
Fig 5. Representative Independent Photography Review: Vis
baseline and year 1 after treatment with polidocanol injectab
B, IPR-V3 photograph at 1 year. Patient 75-1001 was classiﬁe
3 at baseline; he had a median baseline IPR-V3 score of 2 and
(PA-V3) score of 4. At year 1, this patient had IPR-V3 and P
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(measured by the PGIC assessment) who reported clinically
meaningful improvement in their symptoms as well as in
appearance at year 1 compared with visit 5/week 8 is pro-
vided in Fig 6.
The proportion of patients with a duplex ultrasound
response was 89% at visit 5/week 8 and 73% at 1 year.
Duplex ultrasound responders showed greater improve-
ments in the other measures of efﬁcacy compared with
nonresponders. However, duplex ultrasound nonre-
sponders also demonstrated substantial and sustained
improvements in each of the individual symptoms that
compose the VVSymQ score (Fig 7). Overall, the differ-
ence in clinical outcome between duplex ultrasound
responders and nonresponders was small.
Safety. Ten patients of the 232 in the total population
had 12 SAEs reported during the long-term follow-up
period through visit 10/year 1, including one death; all were
unrelated to treatment (Table III). The SAEs were typical of
those events that would be expected in a population of pa-
tients of this age and demographic. Of the patients who had
VTAEs during the main 8-week trial, none had recurrent
VTAEs, and all clots stabilized or resolved completely. No
post-thrombotic syndrome or other clinically important
sequelae were reported. No patient developed a new VTAE
in the 1-year follow-up, and no pulmonary emboli were
diagnosed at any time through 1 year in this study.
DISCUSSION
This publication provides efﬁcacy and safety data at
1 year after treatment for patients who receivedible Varicose Veins (IPR-V3) images, patient 75-1001, at
le foam 1%. A, IPR-V3 photograph at baseline (visit 2).
d clinical, etiologic, anatomic, and pathophysiologic class
baseline Patient Self-assessment of Visible Varicose Veins
A-V3 scores of 1.
Fig 6. Clinically meaningful improvement in symptoms and
appearance at week 8 and at 1 year, patients treated with polidocanol
injectable foam 1% at VANISH-2 baseline (n¼ 57). Symptoms: PGIC
in Symptoms; Appearance Patient: PGIC in Appearance; Appearance
Clinician: CGIC in Appearance. CGIC, Clinician Global Impression
of Change; PGIC, Patient Global Impression of Change.
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study. Twelve months after the ﬁrst treatment with polido-
canol endovenous microfoam, patients reported continued,
clinically meaningful improvement in the primary end
point of symptoms as measured by the VVSymQ score
and the secondary end point of appearance as measured
by IPR-V3 and PA-V3 scores. A small decrease in duplex ul-
trasound response was observed. The U.S. FDA has indi-
cated that clinical evidence of efﬁcacy in the form of
patient-reported outcomes in symptoms and appearance
is of greater importance than the surrogate measure of
duplex ultrasound.13 Whereas the duplex ultrasound
response deﬁnition used in the polidocanol endovenous
microfoam pivotal trials was different from that used inFig 7. Individual Varicose Vein Symptoms Questionnaire (V
ultrasound response, patients treated with polidocanol injectaprevious studies assessing other forms of therapy, loss of
duplex ultrasound response during a 1-year period of the
magnitude seen in this study is comparable to what has
been seen with other treatments.14-16 Duplex ultrasound
response (closure or presence of reﬂux) is a binary response
and does not take into account magnitude. For example,
consider a patient with a large incompetent GSV closed
after treatment with a 1-year duplex ultrasound ﬁnding of
a narrow incompetent channel with low ﬂow. This is prob-
ably not physiologically important and may not be associ-
ated with future worsening, yet it is regarded as
treatment failure by duplex ultrasound, even though there
is a great improvement in hemodynamics and symptoms.
Sustained closure of the treated vein (usually GSV) as re-
ported by heat ablation completely ignores other sources
of incompetence, such as the accessory saphenous veins,
which may cause signiﬁcant hemodynamic problems and
new varicosities. Therefore, duplex ultrasound alone is a
poor measure of treatment success leading to both false-
positive and false-negative results compared with clinical
beneﬁt. Rasmussen et al17 reported duplex ultrasound fail-
ure in a third of patients undergoing foam sclerotherapy for
GSV incompetence, yet the clinical beneﬁts measured by
Venous Clinical Severity Score, Aberdeen Varicose Vein
Questionnaire, and Chronic Venous Insufﬁciency Ques-
tionnaire were identical and sustained to 5 years after
treatment.
What is most important to patients is whether their
symptoms are relieved and whether they are satisﬁed with
the appearance of their legs. As noted, the U.S. FDA has
mandated that these patient-reported outcomes be the
mainstay for assessment of success in the treatment of
varicose veins.13 In this study, the robust efﬁcacy observed
at the primary 8-week time point showed further
improvement at 1 year after treatment with polidocanol
endovenous microfoam 1%.VSymQ) scores at baseline (visit 2) and year 1 by duplex
ble foam 1% at VANISH-2 baseline (n ¼ 56).
Table III. Serious adverse events (SAEs) at 1 year
SAE
No. of
patients
Day of onset (after
initial treatment)
Transient ischemic attack 3 186, 256, 109
Cancer
Breast cancer/mastectomy 1 134
Basal cell carcinoma 1 167
Lymphoma recurrence 1 94
Dehydration 1 331
Genital prolapse 1 169
Diverticulitis 1 89
Cirrhosis, pneumonia,
acute-on-chronic
renal failure (death)
1 174
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Treatment with polidocanol endovenous microfoam
led to durable, clinically meaningful, and ongoing improve-
ments at year 1 in varicose veins as measured by symptoms
(VVSymQ score) and appearance (IPR-V3 [clinician assess-
ment] and PA-V3 [patient self-assessment] scores). SAEs
were those that would be expected during long-term
follow-up of the population of patients studied and were
unrelated to treatment. There were no new VTAEs, no
recurrence or extension of previously diagnosed venous
thrombi, and no clinically important sequelae in patients
who were previously diagnosed with VTAEs. The 1-year
data for patients in VANISH-2 support the conclusion
that venous thrombus after treatment with polidocanol
endovenous microfoam 1% is clinically manageable and
does not result in important clinical sequelae.
The authors acknowledge the writing assistance pro-
vided by Irene Durham and Thomas King and statistical
support provided by Claire Daugherty.
AUTHOR CONTRIBUTIONS
Conception and design: DW
Analysis and interpretation: DW, KT
Data collection: DW, KT
Writing the article: DW
Critical revision of the article: DW
Final approval of the article: DW, KT
Statistical analysis: DW
Obtained funding: DW
Overall responsibility: DW
REFERENCES
1. Jia X, Mowatt G, Burr J, Cassar K, Cook J, Fraser C. Systematic review
of foam sclerotherapy for varicose veins. Br J Surg 2007;94:925-36.2. Cabrera J, Cabrera J Jr, Garcia-Olmedo MA. Sclerosants in microfoam:
a new approach in angiology. Int Angiol 2001;20:322-9.
3. Cabrera J, Cabrera J Jr, Garcia-Olmedo MA, Redondo P. Treatment of
venous malformations with sclerosant in microfoam form. Arch Der-
matol 2003;139:1409.
4. Rabe E, Otto J, Schliephake D, Pannier F. Efﬁcacy and safety of great
saphenous vein sclerotherapy using standardised polidocanol foam
(ESAF): a randomised controlled multicentre clinical trial. Eur J Vasc
Endovasc Surg 2008;35:238-45.
5. Hamel-Desnos C, Desnos P, Wollmann JC, Ouvry P, Mako S,
Allaert FA. Evaluation of the efﬁcacy of polidocanol in the form of foam
compared with liquid form in sclerotherapy of the greater saphenous
vein: initial results. Dermatol Surg 2003;29:1170.e117.
6. Guex J. Complications and side-effects of foam sclerotherapy. Phle-
bology 2009;24:270-4.
7. Sarvananthan T, Shepherd AC, Willenberg T. Neurological compli-
cations of sclerotherapy for varicose veins. J Vasc Surg 2012;55:
243-51.
8. Parsi K. Paradoxical embolism, stroke and sclerotherapy. Phlebology
2012;27:147-67.
9. Bush RG, Derrick M, Manjoney D. Major neurological events
following foam sclerotherapy. Phlebology 2008;23:189-92.
10. Forlee MV, Grouden M, Moore DJ, Shanik G. Stroke after varicose
vein foam injection sclerotherapy. J Vasc Surg 2006;43:162-4.
11. Asbjorgsen CB, Rogers CD, Russell BL. Middle cerebral air embolism
after foam sclerotherapy. Phlebology 2012;27:430-3.
12. U.S. Department of Health and Human Services, Food and
Drug Administration. Guidance for industry: patient-reported
outcome measures: use in medical product development to sup-
port labeling claims; Available at: www.fda.gov/downloads/
Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM
193282.pdf; December 2009; Accessed September 15, 2014.
13. Todd KL 3rd, Wright D, the VANISH-2 Investigator Group. The
VANISH-2 study: a randomized, blinded, multicenter study to
evaluate the efﬁcacy and safety of polidocanol endovenous micro-
foam 0.5% and 1.0% compared with placebo for the treatment of
saphenofemoral junction incompetence. Phlebology 2014;29:
608-18.
14. Christenson JT, Gueddi S, Gemayel G, Bounameaux H. Prospective
randomized trial comparing endovenous laser ablation and surgery for
treatment of primary great saphenous varicose veins with a 2-year fol-
lowup. J Vasc Surg 2010;52:1234-41.
15. Weiss RA, Weiss MA. Controlled radiofrequency endovenous occlu-
sion using a unique radiofrequency catheter under duplex guidance to
eliminate saphenous varicose vein reﬂux: a 2-year follow-up. Dermatol
Surg 2002;28:38-42.
16. Theivacumar NS, Darwood R, Gough MJ. Neovascularisation and
recurrence 2 years after varicose vein treatment for sapheno-femoral
and great saphenous vein reﬂux: a comparison of surgery and
endovenous laser ablation. Eur J Vasc Endovasc Surg 2009;38:
203-7.
17. Rasmussen LH, Lawaetz M, Bjoern L, Vennits B, Blemings A,
Eklof B. Randomized clinical trial comparing endovenous laser
ablation, radiofrequency ablation, foam sclerotherapy and surgical
stripping for great saphenous varicose veins. Br J Surg 2011;98:
1079-87.
Submitted Nov 20, 2014; accepted Mar 1, 2015.
Additional material for this article may be found online
at www.jvsvenous.org.
JOURNAL OF VASCULAR SURGERY: VENOUS AND LYMPHATIC DISORDERS
Volume 3, Number 3 Todd and Wright 264.e1APPENDIX (online only).
The VANISH-2 Investigator Group. K. Gibson,
Bellevue, Wash; M. Goldman, San Diego, Calif; P. Hertzman,
Los Alamos, NM; S. Hirsch, Pittsburgh, Pa; R. Hye,San Diego, Calif; M. Plaza-Ponte, Monroeville, Pa; S.
Rathbun, Oklahoma City, Okla; G. Rosenberg, Frederick,
Md; M. Schul, Lafayette, Ind; M. Stanbro, Greenville, SC;
and R. Weiss, Hunt Valley, Md.
